Market Cap
$1.9B
MESO
MESOBLAST LTD
$14.08 ▼ -1.68%
Prev close $14.32Market cap$1.9B
ConsensusStrong Buy
12-mo target$37.00 (+162.8%)
▲ Bullish
Analyst conviction 9/10
High Impact Filing (7/10)9 New Institutional Positions5 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on MESO right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (90%)
Inst. Holders
50 funds
Inst. Value
$82.3M
Inst. Activity
9 buys / 5 sells
Insider Activity
$30.0M buy / $0.00 sell
Insider Net $
$30.0M
SEC Reports
10
Press Releases
6
Price chart 30d -18.6%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 31, 2026 ftd
Aug 27, 2026 SEC FTD: MESO — 60,075 shares ($1.0M) failed to deliver
Settlement: 20260831, Price: $17.44, FTD Value: $1,047,708, MESOBLAST LIMITED SPONSORED AD
Mesoblast filed its annual 20-F for FY2026, reporting first full-year product revenue of $115.2M from Ryoncil (approved
20-F — Impact 6/10
Mesoblast reported FY2026 total revenue of $120.3M, up 7x from $17.2M in FY2025, driven by the first full year of RYONCI
PRESS-RELEASE — Impact 7/10
Mesoblast filed a 6-K announcing a webcast to discuss operational highlights and financial results for the full year end
6-K — Impact 3/10
Mesoblast completed patient treatment in the pivotal Phase 3 trial (MSB-DR004) of rexlemestrocel-L for chronic low back
Impact 7/10
Mesoblast announced completion of enrollment (at least 300 patients) in its pivotal Phase 3 trial of rexlemestrocel-L fo
Impact 5/10
Jun 30, 2026 Inst.
MORGAN STANLEY — ADD
718,608 shares ($9.7M)
Jun 30, 2026 Inst.
UBS Group AG — ADD
200,053 shares ($2.7M)
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
90% rate it Buy or better · 10 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 27, 2026 | Piper Sandler | REITERATE | Overweight | 54% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Aug 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Jul 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Jun 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| May 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Apr 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Mar 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Feb 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% |
Price targets
Where 2 covering analysts think MESO trades over the next 12 months.
$37.00 +162.8% upside Strong Buy
Current$14.08 Low$35.00 Median$37.00 High$39.00 2 analysts
$35.00$39.00
Analyst rating Buy· 1.7/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
10 SEC filing reports analyzed · 8 bullish, 0 bearish, 1 mixed, 1 neutral · avg impact 5.9/10.Plus 6 press releases.
BULLISH20-F6/10
Mesoblast filed its annual 20-F for FY2026, reporting first full-year product revenue of $115.2M fro
Aug 27, 2026
BULLISHPRESS-RELEASE7/10
Mesoblast reported FY2026 total revenue of $120.3M, up 7x from $17.2M in FY2025, driven by the first
Aug 27, 2026
NEUTRAL6-K3/10
Mesoblast filed a 6-K announcing a webcast to discuss operational highlights and financial results f
Aug 24, 2026
BULLISH6-K6/10
Mesoblast reported Ryoncil net revenue of US$36M for Q4 FY2026 and US$115M for the first full year p
Jul 30, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Aug 31, 2026
ftd
FTD: MESO — 60,075 shares ($1.0M) failed to deliver
Settlement: 20260831, Price: $17.44, FTD Value: $1,047,708, MESOBLAST LIMITED SPONSORED AD
Aug 27, 2026
earnings
Mesoblast Reports Substantial Revenue Growth to US$120M
RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment
Aug 21, 2026
ftd
FTD: MESO — 58,361 shares ($1.0M) failed to deliver
Settlement: 20260821, Price: $17.43, FTD Value: $1,017,232.23, MESOBLAST LIMITED SPONSORED AD
Aug 17, 2026
fda
Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain
NEW YORK, Aug. 16, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory
Aug 13, 2026
ftd
FTD: MESO — 49,098 shares ($0.8M) failed to deliver
Settlement: 20260813, Price: $16.78, FTD Value: $823,864.44, MESOBLAST LIMITED SPONSORED AD
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.08 | $-0.08–$-0.08 | — | -200.0% | 0↑ 1↓ | $0.1B | 1 |
| Next Q | $-0.07 | $-0.07–$-0.07 | — | -187.5% | 0↑ 1↓ | $0.1B | 1 |
| Current FY | $-0.06 | $-0.12–$0.01 | 87.6% | +8.3% | 1↑ 0↓ | $0.3B | 2 |
| Next FY | $0.46 | $0.36–$0.55 | 927.3% | +8.3% | 1↑ 0↓ | $0.4B | 2 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.080 | — |
| 7d ago | $0.080 | -0.160 |
| 30d ago | $0.080 | -0.160 |
| 60d ago | $0.080 | -0.160 |
| 90d ago | $0.080 | -0.160 |
Institutional ownership
Which big funds own MESO (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $82.3M total value (6,082,867 shares) as of 2026-Q2. Top holders: JANE, CITADEL, MORGAN. Net buying activity: 9 institutions added/increased vs 5 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| JANE STREET GROUP, LLC | 1,189,800 | $16.1M | 19.6% | TRIM -66.4% |
| CITADEL ADVISORS LLC | 734,700 | $9.9M | 12.1% | — |
| MORGAN STANLEY | 718,608 | $9.7M | 11.8% | ADD +39.7% |
| BlackRock, Inc. | 664,280 | $9.0M | 10.9% | ADD +25.2% |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 457,744 | $6.2M | 7.5% | — |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 398,000 | $5.4M | 6.5% | — |
| GOLDMAN SACHS GROUP INC | 395,612 | $5.4M | 6.5% | — |
| BNP Paribas Asset Management Holding S.A. | 259,700 | $3.5M | 4.3% | — |
| UBS Group AG | 200,053 | $2.7M | 3.3% | ADD +50.9% |
| Arax Advisory Partners | 168,022 | $2.3M | 2.8% | DOUBLED +587.9% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| MORGAN STANLEY | ADD | 514,431 | 718,608 | +39.7% | $9.7M |
| UBS Group AG | ADD | 132,573 | 200,053 | +50.9% | $2.7M |
| Arax Advisory Partners | DOUBLED | 24,425 | 168,022 | +587.9% | $2.3M |
| Quadrature Capital Ltd | DOUBLED | 17,247 | 53,126 | +208.0% | $718.8K |
| GROUP ONE TRADING LLC | TRIM | 83,915 | 44,030 | -47.5% | $595.7K |
| ROYAL BANK OF CANADA | ADD | 26,266 | 44,003 | +67.5% | $595.0K |
| JANE STREET GROUP, LLC | TRIM | 98,786 | 33,152 | -66.4% | $448.5K |
| Vanguard Personalized Indexing Management, LLC | ADD | 14,009 | 18,407 | +31.4% | $249.0K |
| MARSHALL WACE, LLP | ADD | 11,057 | 17,483 | +58.1% | $236.5K |
| Squarepoint Ops LLC | TRIM | 34,042 | 17,402 | -48.9% | $235.4K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
2 insiders, 25 transactions. Net $30.0M — $30.0M bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 10, 2026 | George Gregory | Director | BUY | 2,324,072 | $1.48 | $3.4M |
| Apr 10, 2026 | George Gregory | Director | BUY | 2,324,072 | $1.48 | $3.4M |
| Apr 9, 2026 | George Gregory | Director | BUY | 10,000 | $14.30 | $143.0K |
| Apr 9, 2026 | George Gregory | Director | BUY | 20,000 | $14.30 | $286.0K |
| Apr 9, 2026 | George Gregory | Director | BUY | 4,760 | $14.40 | $68.5K |
| Apr 9, 2026 | George Gregory | Director | BUY | 10,000 | $1.41 | $14.1K |
| Apr 9, 2026 | George Gregory | Director | BUY | 5,000 | $1.43 | $7.2K |
| Apr 9, 2026 | George Gregory | Director | BUY | 5,240 | $1.43 | $7.5K |
| Apr 9, 2026 | George Gregory | Director | BUY | 10,000 | $1.43 | $14.3K |
| Apr 9, 2026 | George Gregory | Director | BUY | 20,000 | $1.43 | $28.6K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for MESO.
Shares short
3,309,661
Settlement Sep 15, 2026
Change vs prior
+4.7%
Semi-monthly cycle
Days to cover
19.4
At avg daily volume
Of shares outstanding
≈2.5%
Estimate — not % of float
All MESO filing & press-release reports (16)
- 20-F reportAug 27, 2026
- PRESS-RELEASE reportAug 27, 2026
- 6-K reportAug 24, 2026
- PRESS-RELEASE reportAug 17, 2026
- 6-K reportJul 30, 2026
- 6-K reportJul 14, 2026
- PRESS-RELEASE reportJul 14, 2026
- 6-K reportJul 10, 2026
- PRESS-RELEASE reportJul 10, 2026
- 6-K reportJul 3, 2026
- 6-K reportJun 25, 2026
- PRESS-RELEASE reportApr 30, 2026
- PRESS-RELEASE reportApr 29, 2026
- PRESS-RELEASE reportApr 15, 2026
- PRESS-RELEASE reportApr 10, 2026
- PRESS-RELEASE reportApr 8, 2026